NVS

Business Context and Reporting Period

This Form 6-K, dated February 8, 2006, reports the Annual Report for the fiscal year ended December 31, 2005, for Novartis AG, a Swiss-based global healthcare company. The company operates through three primary divisions: Pharmaceuticals (innovative prescription drugs), Sandoz (generic prescription drugs), and Consumer Health (OTC, Animal Health, Medical Nutrition, Gerber, and CIBA Vision). The reporting period reflects the company's tenth anniversary since its formation, highlighting a strategic transformation from a diversified conglomerate to a focused healthcare leader.

Key Financial Metrics (2005 vs. 2004 Pro Forma)

Liquidity and Debt: Net liquidity decreased by USD 4.6 billion to USD 2.5 billion at year-end, primarily due to significant acquisitions. Total financial debt increased by USD 1.6 billion to USD 8.5 billion, resulting in a debt-to-equity ratio of 0.25:1. The company maintains AAA/Aaa credit ratings.

Material Changes and Divisional Performance

• Pharmaceuticals: Net sales grew 10% to USD 20.3 billion, driven by double-digit growth in Cardiovascular (Diovan, Lotrel) and Oncology (Gleevec/Glivec, Zometa, Femara) franchises. Operating income rose 12% to USD 6.0 billion, with margins improving to 29.7%.
• Sandoz: Net sales surged 54% to USD 4.7 billion, largely due to the acquisitions of Hexal AG and Eon Labs, Inc. Operating income increased 30% to USD 342 million, though margins were impacted by acquisition-related costs and amortization.
• Consumer Health: Net sales climbed 8% to USD 7.3 billion, supported by the acquisition of the North American OTC business of Bristol-Myers Squibb and strong performance in strategic brands. Operating income rose 5% to USD 1.1 billion.
• Acquisitions: The company spent approximately USD 8.8 billion on acquisitions in 2005, including Hexal, Eon Labs, and the BMS OTC business. A definitive merger agreement to acquire the remaining shares of Chiron Corporation was announced in October 2005.

Guidance, Outlook, and Risks

Outlook and Pipeline: Management expects continued growth driven by a robust pipeline of 76 compounds, with 50 in late-stage trials. Key upcoming filings in 2006 include Galvus (type 2 diabetes), Rasilez (hypertension), and Exforge (hypertension combination). The company aims to expand its vaccines business following the pending Chiron acquisition.

Dividend: A dividend of CHF 1.15 per share was proposed, representing a 10% increase and the ninth consecutive year of dividend growth.

Risks and Contingencies:

• Regulatory and Pricing: The company faces pressure from government price controls, mandatory discounts, and the promotion of generics, which may impact margins.
• R&D Setbacks: Clinical trials for PTK787 (colorectal cancer) fell short of expectations, and development of pitavastatin was terminated, highlighting the risks inherent in drug development.
• Legal and Litigation: The company is subject to various litigation, including product liability claims (e.g., Fen-Phen, PPA), patent disputes, and investigations into marketing practices (e.g., US enteral pump industry settlement).
• Environmental: Provisions exist for environmental remediation costs at various sites, though management believes these are adequate.

Investor Verification Checklist

• Verify the integration progress and synergy realization of the Hexal and Eon Labs acquisitions within the Sandoz division.
• Monitor the regulatory approval status and commercial launch of key pipeline products: Galvus, Rasilez, and Exforge.
• Assess the impact of the pending Chiron Corporation acquisition on the company's vaccine portfolio and financial leverage.
• Review the status of ongoing litigation, particularly regarding Fen-Phen, PPA, and marketing practice investigations.
• Track the company's ability to maintain R&D productivity and manage costs amidst increasing government pricing pressures.